Two of the world’s biggest drugmakers — AstraZeneca and MSD — have hailed progress in tackling hard-to-treat cancers, ...

If the trial design doesn't cause regulatory issues, the results could reshape how muscle-invasive bladder tumors are treated ...

London-listed AstraZeneca shares fell more than 5% on Tuesday after results from the company's lung cancer trials showed that ...

AstraZeneca (LSE:AZN) is navigating a period of robust growth and strategic challenges. Recent developments include an 18% ...

Chinese authorities have detained AstraZeneca employees amid a probe into potential data privacy breaches and unlicensed drug ...

Since GSK’s Nucala and AstraZeneca’s Fasenra were approved two years apart ... Some other key metrics favored AZ’s medicine.

AstraZeneca Plc shares are on track for their biggest weekly decline since July 2023, after a disappointing update for the ...

The partners’ ADC didn’t significantly extend survival in lung cancer patients who were expected to benefit the most from treatment in a Phase 3 trial.

AstraZeneca’s Fasenra (benralizumab ... “This trial demonstrates that a biologic medicine given in a single monthly injection ...

AstraZeneca has announced that FluMist has been approved in the US as the self-administered influenza vaccine. FluMist, a ...

Meet the Management at ESMO 2024 Conference September 16, 2024 2:00 PM ETCompany ParticipantsPascal Soriot - Chief ...

FluMist approved for self-administration in the US Only influenza vaccine approved for self- or caregiver-administration at home, expanding options for influenza protection FluMist ...